Clinical outcomes of endoscopic submucosa dissection for high-grade dysplasia from endoscopic forceps biopsy

In recent years, endoscopic submucosal dissection (ESD) has become an accepted curative treatment modality for the treatment of high-grade dysplasia (HGD) or early gastric cancer (EGC) without lymph node metastasis. ESD is preferred because it is less invasive and expensive and results in a better quality of life compared with surgical gastric resection. In order to treat EGC by ESD, early detection of EGC or dysplastic lesions is essential, especially in countries where gastric cancer is highly prevalent. In South Korea, the National Cancer Screening Program is in operation and biennial esophago-gastro-duodenal endoscopy is recommended for men and women over 40 years old. With the widespread availability of screening endoscopy, early detection of precancerous lesions and EGC has increased. In South Korea, the proportion of stage IA patients has increased by ~57% during the last 10 years [1, 2].

Gastric adenoma/dysplasia is regarded as a precancerous lesion. The risk of carcinoma generally increases with the histological grade of the dysplasia (low to high grade) [3]. Gastric HGD (category 4 in the Vienna Classification) is highly predictive of invasive carcinoma, which either coexists or appears within a short time after biopsy. Therefore, from the revised Vienna Classification, HGD should be removed by endoscopic resection [4]. Although an endoscopic forceps biopsy (EFB) is the best method to diagnose EGC, the misdiagnosis rate of EFB specimens for gastric superficial neoplasm is reported to be up to 40–55% [5, 6]. If the pathologic result after ESD subsequently shows gastric cancer, additional surgical treatment may be considered according to the pathological type (well vs. poorly differentiated adenocarcinoma), depth of invasion (mucosal cancer or submucosal invasive cancer or lymphatic invasion), or resection margin status (free resection margin vs. involved resection margin). However, there is no way to determine the submucosal or lymphatic invasion accurately before endoscopic resection.

In the present study, we retrospectively evaluated the final ESD outcomes of gastric HGD from EFB and analyzed the endoscopic characteristics associated with invasive EGC after ESD.

The patients’ mean age was 63.89 ± 8.53 years. The range of tumor size was 2–65 mm (median 12.59). The main location of the lesions was the lower third of the stomach (Table 1). En bloc resection and complete resection rates were 97.4% (416/427) and 95.3% (407/427). The diagnostic discrepancy rate was 76.3% (326/427). The up- and downgrade rates of the pathological diagnosis were 66.5% (284/427) and 9.8% (42/427), respectively. Among those undergoing EGC after ESD, 38 lesions were found to be submucosal invasive lesions (including 6 with lymphovascular invasion). Among the submucosal invasive lesions, 15 patients underwent additional operations, and lymph node metastasis was found in 3 patients (Fig. 2).

Endoscopic characteristics associated with EGC were analyzed (Table 2). Multivariate analysis revealed that central depression [OR 4.151 (95% CI 2.340–7.363)], nodular surface [OR 5.582 (95% CI 3.230–9.649)], surface redness [OR 2.926 (95% CI 1.747–4.901)], lesion location (upper third of the stomach) [OR 3.894 (95% CI 1.110–13.666)], and larger tumor size (≥10 mm) [OR 2.287 (95% CI 1.387–3.770)] were significantly associated with EGC. Multivariate analysis revealed that surface nodularity [OR 2.746 (95% CI 1.246–6.053)], submucosal fibrosis [OR 3.958 (95% CI 1.822–8.596)], lesion location (upper third of the stomach) [OR 13.051 (95% CI 3.229–52.754)], and larger tumor size (≥10 mm) [OR 6.652 (95% CI 2.357–18.772)] were significant factors associated with submucosal invasive cancer (Table 3). A case of diagnosis upgraded to deep submucosal invasive cancer after ESD is illustrated in Fig. 3.

On follow-up at 3–6 months after endoscopic resection, a Helicobacter pylori (HP) test (rapid urease test or biopsy or blood antibody test or urea breath test) was performed in all patients. Absence of infection was defined by two consecutive negative HP test results, with one positive result being considered as a case of infection. We identified an incidence rate of HP infection of 58.1% (248/427 cases). Among patients with no HP infection, 35.8% (64/179) of patients had received prior HP treatment. However, there was no difference in the rate of HP infection between the final HGD group and EGC group. Moreover, there was no difference in HP infection rate between the final HGD group and SM invasive cancer group (Tables 2, 3).

Since ESD has been widely implemented for the treatment of EGC, early detection of precancerous lesions such as HGD has been more important. In recent years, more than 50% of gastric cancers have been detected as EGC in South Korea [1, 2]. Although EFB can be used as a basic diagnostic tool for the initial treatment of gastric superficial neoplasm, gastric HGD (category 4 in the Vienna Classification) is shown to be cancer in about 27.6–80% of cases after endoscopic resection [6, 9, 10]. The possible reasons for this discrepancy may be as follows. First, forceps biopsy samples are small and do not represent the entire lesion. Second, cancer sometimes exists as hidden foci in other parts of the lesion. Third, the atypia of adenoma and adenocarcinoma is too subtle to detect in a small biopsy specimen [6]. Fourth, accurate targeted biopsy through EFB can be difficult because of the location of lesions. In the present study, 66.5% (284/427) of lesions had the diagnosis upgraded to EGC after ESD. Furthermore, 8.9% (38/427) of lesions were diagnosed as submucosal invasive cancer.

To accept ESD as a treatment of EGC, the risk of lymph node metastasis must be absent. However, the presence of lymph node metastasis can be confirmed after surgical gastrectomy with lymph node dissection. EGC is a gastric cancer limited to the mucosa or submucosa, irrespective of the presence of lymph node metastasis. Submucosal and lymphovascular invasions are independent risk factors for lymph node metastases [11, 12]. Therefore, these findings are critical prognostic factors in patients with EGC. Submucosal invasion has been reported as an independent risk factor for lymphovascular invasion in endoscopically resected EGC, and the incidence of lymph node metastasis is significantly higher in submucosal invasive EGC [13]. This can be explained by the particular distribution of lymph capillaries in the mucosal layer. Although lymph capillaries are found in the deep lamina propria adjacent to and within the muscularis mucosa, most large lymph vessels are located in the submucosa [14]. However, there is no way to precisely evaluate submucosal or lymphovascular invasion before ESD. Recent reports examining the long-term outcomes of endoscopic resection for EGC (differentiated-type adenocarcinoma; no surface ulceration; a diameter of ≤2 cm; limited to the mucosa) showed comparable overall survival with surgery [15, 16]. For the endoscopic treatment of EGC, Japanese [17] and South Korean [18] gastric cancer treatment guidelines are almost the same. According to the guidelines, ESD is indicated as a standard treatment for lesions meeting the following criteria (absolute indications): (1) lesions limited to the mucosal layer, (2) well and/or moderately differentiated adenocarcinomas, (3) tumors ≤2 cm in length, (4) absence of ulceration or ulcer scar tissue, and (5) tumors without lymphovascular involvement.

In the present study, risk factors associated with EGC after ESD for HGD lesions were central depression, nodular surface, surface redness, large tumor size (≥1 cm), and tumor location in the upper third of the stomach. Additionally, associated factors with submucosal invasive EGC were nodular surface, submucosal fibrosis, tumor location in the upper third of the stomach, and larger tumor size (≥10 mm). As lesions progress, structural changes appear. Central depression and a nodular surface are associated with lesion progression [19]. Surface redness is associated with the development of vascular structures with disease progression [3]. Large tumor size is a known risk factor for EGC in adenoma, which can be understood as the size increases with disease progression [5]. However, we do not definitely know why the location of a lesion in the upper third of the stomach was a significant risk factor associated with EGC. Before now, some studies have shown that ESD is more difficult to treat and causes more complications if the lesion is located in the upper portion of the stomach [20]. A possible explanation for this is the technical factors associated with the endoscopic experience. EGC located in the lower third of the stomach, especially in the antrum, might be easily detected, but to detect EGC in the upper third of the stomach, more practical experience with endoscopic procedures might be required. Therefore, EGC lesions located in the upper third of the stomach might have a delayed or missed diagnosis. In addition, targeted biopsy of lesions located in the upper third of the stomach is difficult. Further studies might be required to clearly explain the reasons for this finding. Furthermore, we found that 38 submucosal invasive cancers were wrongly diagnosed as HGD in this study (8.9%, 38/427). Risk factors associated with submucosal invasive cancer were submucosal fibrosis, large tumor size, and tumor location in the upper third of the stomach. Adenocarcinomas were more closely related to submucosal fibrosis than were adenomatous lesions. A previous study reported that fibroblasts and myofibroblasts cause fibrosis of the submucosa as a result of the desmoplastic response to cancers [21]. A previous study had shown that submucosal invasive cancer causes submucosal fibrosis [22], and our study also indicates that submucosal invasion is closely related to submucosal fibrosis. As described above, lesions located in the upper part of the stomach are difficult to find and to perform targeted biopsy. Differences in wall thickness according to the location in the stomach might be associated with these results. The whole wall thickness is thicker in the antrum than in the body and cardia, and the thickness of the submucosal layer decreases from the antrum to the cardia and the body [23]. Thus, an EGC located in the upper portion of the stomach might be a deep invasive cancer even though it is the same size.

There are several limitations to this study. First, it was retrospectively conducted in a single center. The sample size of lesions might be too small for supporting these risk factors definitely. However, the identified risk factors, including other studies so far, may be helpful for further studies and provide evidence for caution with endoscopic treatment of EGC. Second, we used the conventional endoscopic appearances of the lesion for the analysis. If recent diagnostic technologies such as IEE were used, more accurate diagnoses may have been given.

In summary, because gastric HGD is a precancerous lesion and has a high rate of diagnosis upgrading to EGC, it should be removed. Risk factors associated with EGC were central depression, nodular surface, surface redness, tumor location (upper third of the stomach), and large tumor size. Furthermore, if submucosal fibrosis is suspected, the probability of submucosal invasive cancer increases. Therefore, for lesions with these risk factors, physicians should be cautious before deciding to treat with ESD. Patients should also be informed of the risks and benefits of undergoing more invasive treatments such as surgical gastrectomy with lymph node dissection.